Sugi Predict

Sugi Predict / Compounds / SCHEMBL1554780

SCHEMBL1554780

SCHEMBL1554780

CC(C)(C)OC(=O)N1CCC(C(=O)CC#N)CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.71
▸ KMT2A Q03164 2/20 0.71
▸ MEN1 O00255 1/20 0.71
▸ ALDH1A1 P00352 1/20 0.71
▸ HPGD P15428 1/20 0.55
▸ RECQL P46063 1/20 0.52
▸ PTPN2 P17706 1/20 0.48
▸ PTPN1 P18031 1/20 0.48
▸ PTPN6 P29350 1/20 0.48
▸ EPHX1 P07099 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ GPR119 Q8TDV5 4/20 0.45
▸ DPP4 P27487 1/20 0.45
▸ STS P08842 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CTSK P43235 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6223051 0.92 MAPT (0.85) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL10255766 0.85 MAPT (0.75) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL11931428 0.83 MEN1 (1.00) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL16604392 0.81 HPGD (0.60) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL6105130 0.81 HPGD (0.60) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL20353737 0.80 HPGD (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL3296996 0.80 HPGD (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL1002397 0.80 HPGD (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL14622828 0.80 HPGD (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL583820 0.80 MEN1 (0.54) MAPTKMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260007680-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2026-01-08 — — US disclosed
EP-4619406-A1 TRICYCLIC COMPOUNDS Schrödinger, Inc. (US) 2025-09-24 — — EP disclosed
US-20250171432-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-29 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
EP-4469447-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240391899-A1 POTENT AND SELECTIVE INHIBITORS OF IRAK4 DANA FARBER CANCER INST INC (US) 2024-11-28 — — US disclosed
WO-2011045344-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PIERRE FABRE MEDICAMENT (FR) 2011-04-21 — — WO disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 — — US disclosed
EP-2265610-A1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 — — EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 — — US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 — — US disclosed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 — — WO disclosed
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 — — US disclosed
EP-1537106-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2005-06-08 — — EP disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 — — US disclosed
WO-2004014910-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS MITSUBISHI PHARMA CORPORATION (JP) 2004-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885KMT2A 445/4885MEN1 4055/4885
US-20260007680-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B MAPT 4801/4885KMT2A 3586/4885MEN1 3060/4885
US-20240391899-A1 POTENT AND SELECTIVE INHIBITORS OF IRAK4 IRAK4, IRAK1, IRAK2 MAPT 2549/4885KMT2A 1440/4885MEN1 3311/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885KMT2A 445/4885MEN1 4055/4885
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 MAPT 1941/4885KMT2A 2152/4885MEN1 1111/4885
US-20250171432-A1 COMPOUNDS AND METHODS OF USE ABCG2, F12, CYP2C9 MAPT 2894/4885KMT2A 4167/4885MEN1 75/4885
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS BRAF, RAF1, ARAF MAPT 946/4885KMT2A 3704/4885MEN1 1680/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN MAPT 2959/4885KMT2A 2453/4885MEN1 164/4885
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB MAPT 96/4885KMT2A 3396/4885MEN1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.